Ofatumumab was found to have greater efficacy than teriflunomide for the treatment of patients with newly diagnosed relapsing multiple sclerosis.
Effectiveness of disease modifying therapies for multiple sclerosis was shown to be associated with shorter disease duration and lower relapse rate.
In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.
A network of gut bacteria species may be associated with host genetic factors that increase susceptibility to multiple sclerosis.
More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than disability worsening.
The onset of hyperlipidemia may occur earlier in patients with multiple sclerosis.
Patients who have been diagnosed with and treated for multiple sclerosis (MS) have an increased risk for any type of infection, with the highest risk being for renal tract infections.
Researchers sought to find any genetic variants associated with migraine or MS that could be identified from genome-wide association studies.
Fatigue, anemia, pain, and sleep disorders form part of the prodrome in MS.
Home telehealth may be a feasible and safe option for veterans with multiple sclerosis who have difficulty accessing services from the VA or community services.
Patients with vs without multiple sclerosis were found to be at increased risk for several cardiac events.
Roughly half of patients with pediatric-onset multiple sclerosis (MS) who transition to adult clinics experience worsened clinical disability.
Using newer disease-modifying therapies for the initial treatment of pediatric multiple sclerosis may be more effective than injectables at controlling disease activity.
The researchers concluded that patients with both MS and depression experience worsening in neurological function, relapses, and lesions activity after 1 year compared with patients without depression.
Researchers of the study assessed the sensitivity and specificity of the STOP-Bang tool in patients with MS.